CN116211902B - 一种具有舒缓修护功能的九节茶提取物及其制备方法和用途 - Google Patents
一种具有舒缓修护功能的九节茶提取物及其制备方法和用途 Download PDFInfo
- Publication number
- CN116211902B CN116211902B CN202310434537.8A CN202310434537A CN116211902B CN 116211902 B CN116211902 B CN 116211902B CN 202310434537 A CN202310434537 A CN 202310434537A CN 116211902 B CN116211902 B CN 116211902B
- Authority
- CN
- China
- Prior art keywords
- extract
- pileae scriptae
- skin
- herba
- herba pileae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 97
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 230000006870 function Effects 0.000 title description 6
- 230000000694 effects Effects 0.000 claims abstract description 20
- 238000004140 cleaning Methods 0.000 claims abstract description 17
- 239000000047 product Substances 0.000 claims description 37
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000741 silica gel Substances 0.000 claims description 14
- 229910002027 silica gel Inorganic materials 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000003480 eluent Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 9
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 9
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- HOEVRHHMDJKUMZ-UHFFFAOYSA-N Isofraxidin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2OC HOEVRHHMDJKUMZ-UHFFFAOYSA-N 0.000 claims description 8
- ANCHXLMTFNOVDK-UHFFFAOYSA-N Isofraxidin Natural products COC1=C(O)C(OC)=CC2=C1OC=CC2=O ANCHXLMTFNOVDK-UHFFFAOYSA-N 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 240000004274 Sarcandra glabra Species 0.000 claims description 5
- 238000004440 column chromatography Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 239000000287 crude extract Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 241000758719 Chloranthaceae Species 0.000 claims description 3
- 235000010842 Sarcandra glabra Nutrition 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 42
- 241000252212 Danio rerio Species 0.000 abstract description 22
- 210000000214 mouth Anatomy 0.000 abstract description 10
- 238000012546 transfer Methods 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 55
- 230000001815 facial effect Effects 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 244000269722 Thea sinensis Species 0.000 description 8
- 230000036572 transepidermal water loss Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 235000008734 Bergera koenigii Nutrition 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 240000002393 Murraya koenigii Species 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004042 decolorization Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 230000007480 spreading Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- -1 coumarin, phenolic acids Chemical class 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000736026 Sarcandra Species 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 244000146553 Ceiba pentandra Species 0.000 description 1
- 235000003301 Ceiba pentandra Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 235000016787 Piper methysticum Nutrition 0.000 description 1
- 240000007653 Pometia tomentosa Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000007673 developmental toxicity Effects 0.000 description 1
- 231100000415 developmental toxicity Toxicity 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- FMYHFHVAPZDDPJ-UHFFFAOYSA-N ethanol;ethyl acetate;hydrate Chemical compound O.CCO.CCOC(C)=O FMYHFHVAPZDDPJ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000009291 xinhuang Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种具有舒缓修护功能的九节茶提取物及其制备方法和用途。与现有技术相比,本发明九节茶提取物制备方法具有操作简便、提纯效率高等优点;制得的九节茶提取物颜色较浅,有效成分转移率较高,经斑马鱼及人体舒缓修护功效测试表明,该九节茶提取物较少添加量即具有较强的舒缓和修护皮肤效果,能广泛应用于包括口腔清洁类产品在内的体外各类型舒缓修护皮肤外用产品中。
Description
技术领域
本发明属于中药提取技术领域,具体涉及一种具有舒缓修护功能的九节茶提取物及其制备方法和用途。
背景技术
九节茶(Sarcandra glabra(Thunb.)Nakai)为金粟兰科(Chloranthaceae)草珊瑚属(Sarcandra)植物,又名肿节风、接骨金粟兰和草珊瑚等,主要分布于云南、贵州、福建、江西、海南等地。全株可入药,自1977年以来一直收录于《中国药典》一部,其味苦,性平,入心、肝经,具有清热解毒、祛风除湿、活血祛瘀、通经接骨等功效。毒理学研究表明,九节茶提取物具有较好的安全性,目前临床上九节茶主要用于治疗胃溃疡、痢疾、肿瘤、骨折及各种口腔疾病。经现代化学分析技术研究发现,其提取物主要含有萜类、黄酮类、香豆素、酚酸类等类别的组分。近年来,已有不同研究证实九节茶植株中所含的活性成分具有抗真菌、抗肿瘤、抗感染、抗病毒等作用。九节茶应用广泛,在肿节风片、新癀片、清热消炎宁胶囊和复方九节茶含片等多种中成药中都是重要原料。其中异嗪皮啶作为九节茶其中一种主要成分,为简单香豆素类化合物,现代研究表明异嗪皮啶具有清热解毒、抗菌抗炎、祛风除湿、活血散瘀等功效,对治疗肺癌和直肠癌等一些肿瘤有明显效果;九节茶另一化学成分为迷迭香酸,作为天然抗氧化剂,迷迭香酸可抑制脂质过氧化。由于其在防御机制和适应生物体内过程中的作用,迷迭香酸的应用被扩展到营养和人类健康领域,在许多慢性疾病的预防和治疗上也展现出很高的医学前景。
目前九节茶的研究内容均基于九节茶中草药药理、口服药临床应用等方面,现有技术所提供的九节茶浸膏也局限于药品和健康食品行业。此外,九节茶提取物颜色较深,会在皮肤及牙齿表面着色且不易清洁,影响皮肤和牙齿的美观,故难以直接应用于各类皮肤外用产品和口腔牙齿清洁类产品中,目前尚未见将九节茶提取物脱色提纯后用于包括化妆品在内的皮肤外用(含口腔清洁类)产品方面的相关报道。
发明内容
为克服现有技术的缺点和不足,本发明提供了一种具有舒缓修护作用的九节茶提取物及其制备方法和在皮肤外用(含口腔清洁类)产品中的应用。本发明的九节茶提取物为九节茶药材提取浓缩后经柱层析技术脱色处理,最后应用至各类皮肤外用(含口腔清洁类)产品中。
具体地,通过以下几个方面的技术方案实现了本发明:
在第一个方面中,本发明提供了一种九节茶提取物的制备方法,所述九节茶提取物的制备方法包括以下步骤:
步骤1:提取和浓缩:取九节茶净药材,粗碎后投入提取罐内煎煮,加5-20倍量水煎煮1-10小时,从沸腾后开始计时,煎液过滤,合并滤液,将滤液在减压装置下≤80℃浓缩即得九节茶粗浸膏,即提取物A。
作为可选的方式,所述九节茶提取物的制备方法还包括以下步骤:
步骤2:提纯和脱色:将步骤1中制备得到的所述提取物A加入适量硅胶,拌样后经硅胶柱层析用4-6倍柱体积的层析液体积分数40%-95%乙醇-水溶液洗脱,收集洗脱液浓缩,得浓缩液,即提取物B;将所述提取物B加入适量硅胶,拌样后经硅胶柱层析第一次用2-3倍柱体积的石油醚洗脱,弃去洗脱液,第二次用4-6倍柱体积的乙酸乙酯:乙醇:水=75%-89%:20%-10%:1%混合溶液洗脱,收集洗脱液浓缩,得浓缩液,即提取物C。
作为可选的方式,在上述制备方法中,所述九节茶净药材为金粟兰科植物九节茶Sarcandra glabra(Thunb.)Nakai的干燥全草。
作为可选的方式,在上述制备方法中,在步骤2中的所述浓缩均在减压装置下≤80℃进行,所述提取物C中迷迭香酸与异嗪皮啶的重量比为10-13:1。
在一个优选实施方式中,所述九节茶提取物的制备方法包括以下步骤:
步骤1:称取一定量的九节茶净药材,粗碎后投入提取罐内煎煮,加12倍量水煎煮4小时,从沸腾后开始计时,煎液过滤,合并滤液,将滤液在减压装置下75℃浓缩即得九节茶粗浸膏提取物A;
步骤2:将所述提取物A加入适量硅胶,搅拌后均匀铺至硅胶柱上方,用5倍柱体积的80%乙醇洗脱,收集洗脱液减压浓缩75℃,得提取物B;将提取物B与适量硅胶粉搅拌,均匀铺至另一硅胶柱上,第一次洗脱用3倍柱体积的石油醚洗脱,弃去洗脱液,第二次洗脱用5倍柱体积的乙酸乙酯:乙醇:水=84:15:1混合溶液洗脱,收集洗脱液减压浓缩75℃,即得九节茶提取物,即提取物C。
在第二个方面中,本发明提供了一种具有舒缓修护功能的九节茶提取物,所述九节茶提取物是由上述第一个方面所述的方法制备得到的。
作为可选的方式,在上述九节茶提取物中,所述九节茶提取物是颜色为淡黄色的所述提取物C,所述提取物C中迷迭香酸与异嗪皮啶的重量比为10-13:1。
在第三个方面中,本发明提供了上述第二个方面所述的九节茶提取物在制备具有舒缓修护功能的皮肤外用(含口腔清洁类)产品中的用途。
作为可选的方式,这里所述的“皮肤”不仅包括覆盖动物或人的脸或身体表面的组织,而且还包括头皮和毛发。
作为可选的方式,在上述用途中,所述皮肤外用(含口腔清洁类)产品为药物、化妆品或洗护用品。
作为可选的方式,在上述用途中,所述化妆品为爽肤水、乳液、精华、面霜、润肤露、护手霜或面膜等。
作为可选的方式,在上述用途中,所述洗护用品为洗手液、沐浴露、洗发水、洗发露或护发素、牙膏、漱口水等。
作为可选的方式,在上述用途中,以重量百分比计,所述九节茶提取物在所述皮肤外用(含口腔清洁类)产品中的用量为0.01%-3.12%。
以重量百分比计,具体用量可以为0.01、0.02、0.05、0.10、0.20、0.30、0.50、0.80、1.00、1.20、1.50、1.80、2.00、2.20、2.50、2.80、3.00或3.12%。
作为可选的方式,在上述用途中,所述皮肤外用(含口腔清洁类)产品为固体、溶液、乳液、悬浮液、霜、凝胶、浆糊、泡沫或喷雾形式。这些剂型可以通过本领域所熟知的任何常用方法来制备。
在上述方案的基础上,所述皮肤外用(含口腔清洁类)产品可以包含其他能够提高所述皮肤外用产品主要效果且不影响主要效果的成分。具体的,所述的皮肤外用产品中还包含除九节茶提取物之外的具有舒缓修复皮肤功效的成分、抗衰老成分、抗氧化剂、维生素、多肽、多糖或鞘脂中的一种或多种。
此外,所述皮肤外用(含口腔清洁类)产品还可以包含保湿剂、润肤剂、表面活性剂、紫外吸收剂、防腐剂、消毒剂、抗氧化剂、pH调节剂、有机和/或无机颜料、调味剂、冷却剂、止汗剂等。在不影响本发明的目的及效果的前提下,本领域的技术人员可容易地选择所述皮肤外用产品中的上述组合物的含量。
所述皮肤外用(含口腔清洁类)产品可以为适于局部涂抹的任何剂型。例如,所述皮肤外用(含口腔清洁类)产品可以为固体、溶液、乳液(水包油型乳液、油包水型乳液)、悬浮液、霜、凝胶、浆糊或喷雾等形式,但不限于这些剂型。根据本领域所熟知的任何常用方法,可以通过使用表面活性剂、赋形剂、保湿剂、乳化剂、悬浮剂、用于渗透压的盐或缓冲剂、着色剂、调味剂、稳定剂、防腐剂或其他常用的添加剂来制备所述皮肤外用(含口腔清洁类)产品的剂型。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。限于篇幅,在此不再一一赘述。
本发明相对于现有技术,具有以下有益效果:
本发明提供了一种具有舒缓修护功能的九节茶提取物及其制备方法和用途。与现有技术相比,本发明九节茶提取物制备方法具有操作简便、提纯效率高等优点;制得的九节茶提取物颜色较浅,有效成分转移率较高,经斑马鱼及人体舒缓修护功效测试表明,该九节茶提取物较少添加量即具有较强的舒缓和修护皮肤效果,能广泛应用于体外各类型舒缓修护皮肤外用(含口腔清洁类)产品中。
附图说明
图1:九节茶提取物脱色前后对比图。其中,1:提取物A(脱色前);2:提取物C(脱色后)。
图2:TNF-α基因相对表达量柱形图。其中,与模型对照组比较,***p<0.001。
图3:九节茶提取物C修护典型图。其中,红色实线部位为定量区域。
图4:部分受试者面部红区图。
图5:部分受试者自然光拍摄图。
具体实施方式
下面参照具体的实施例对本发明做进一步说明。应当理解,此处所描述的具体实施例仅用于解释本发明,并不用于限定本发明的范围。
实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件,或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可通过正规渠道购买得到的常规产品。
下面实施例中的实验方法,如无特殊说明,均为常规方法。下述实施例中所用的试验材料,如无特殊说明,均为市售产品。
实施例1:九节茶提取物的制备方法
步骤1:称取一定量的九节茶净药材,粗碎后投入提取罐内煎煮,加12倍量水煎煮4小时(从沸腾后开始计时),煎液过滤,合并滤液。将滤液在减压装置下(75℃)浓缩即得九节茶粗浸膏(提取物A)。
步骤2:将上述提取物A加入适量硅胶,搅拌后均匀铺至硅胶柱上方,用5倍柱体积的80%乙醇洗脱,收集洗脱液减压浓缩(75℃),得提取物B;将提取物B与适量硅胶粉搅拌,均匀铺至另一硅胶柱上,第一次洗脱用3倍柱体积的石油醚洗脱,弃去洗脱液,第二次洗脱用5倍柱体积的乙酸乙酯-乙醇-水(84:15:1)混合溶液洗脱,收集洗脱液减压浓缩(75℃),即得九节茶提取物(提取物C)。
九节茶提取物C颜色为淡黄色,与提取物A的对比图见图1。
步骤2所得九节茶提取物C中异嗪皮啶和迷迭香酸的转移率及含量比计算。
经本发明提供的制备方法制得九节茶提取物C中异嗪皮啶和迷迭香酸的转移率及含量比见表1。上述实验结果表明,制得的九节茶提取物颜色较浅,有效成分转移率较高。
表13批九节茶提取物C异嗪皮啶和迷迭香酸的转移率及含量比
实施例2:实施例1中步骤2所得九节茶提取物C对斑马鱼最大检测浓度(MTC)试验
斑马鱼是目前在人类健康和生态危害评估中使用替代物种之一。斑马鱼和人类基因有着87%的高度相似性,是除大鼠和小鼠外的第三大模式生物,其受环境和化合物影响出现死亡和发育毒性,因此可通过斑马鱼死亡情况和毒性情况可确定样品的最大检测浓度(MTC)。
随机选取受精后2天(2dpf)转基因中性粒细胞绿色荧光斑马鱼(MPX)于六孔板中,每孔15尾,水溶给予九节茶提取物C样品,同时设置正常对照组,每孔容量为3mL,于28℃条件下避光孵育18h,根据斑马鱼死亡情况和毒性情况,确定九节茶提取物C对正常斑马鱼的MTC。
在本次实验条件下,九节茶提取物C对正常斑马鱼的MTC为3.12%,结果见表2。
表2九节茶提取物C对斑马鱼最大检测浓度(MTC)试验
实施例3:实施例1中步骤2所得九节茶提取物C的舒缓功效评价试验
十二烷基磺酸钠(SLS)作用于机体后可能引发机体产生刺激反应,可导致水肿、红斑、瘙痒、疼痛等症状。对皮肤的刺激表型主要表现为皮肤炎症,炎症早期主要表现为毛细血管扩张、通透性亢进和水肿。刺激物进入斑马鱼体内,诱导炎症反应。TNF-α是炎症反应过程中出现最早、最重要的炎性细胞因子,能激活中性粒细胞。因此,可通过检测TNF-α基因相对表达量来评价样品是否具有舒缓功效。
随机选取受精后2天(2dpf)转基因中性粒细胞绿色荧光斑马鱼(MPX)于六孔板中,每孔30尾,水溶给予十二烷基磺酸钠(SLS)溶液,建立斑马鱼皮肤炎症模型。水溶给予九节茶提取物C,同时设置正常对照组和模型对照组,每孔容量为3mL。三次生物学重复。于28℃条件下避光孵育18h后,提取各实验组斑马鱼总RNA,合成cDNA,利用q-PCR检测β-actin和目的基因的基因表达,用β-actin作为基因表达的内参,计算目的基因的RNA相对表达量,结果见表3,统计学分析p<0.05,判定为有显著性差异。该样品功效实验柱形图,如图2所示。
表3九节茶提取物C舒缓功效评价试验
在本次实验条件下,九节茶提取物C的TNF-α基因相对表达量与模型对照组相比,明显减少,揭示了该样品具有舒缓功效。
实施例4:实施例1中步骤2所得九节茶提取物C的修护功效评价试验
将斑马鱼尾鳍进行机械损伤后,断尾诱导炎症反应,中性粒细胞发生免疫应答,向伤口迁移并聚集。通过手术刀沿与躯干垂直方向切断尾鳍,添加样品作用一定时间后,以转基因中性粒细胞绿色荧光品系斑马鱼尾鳍附近中性粒细胞数量来表征样品的修护功效。
选取受精后3天(3dpf)转基因中性粒细胞绿色荧光斑马鱼(MPX)于六孔板中,每孔15尾,用手术刀切除斑马鱼的尾鳍建立斑马鱼尾鳍损伤炎症模型。水溶给予九节茶提取物C,同时设置正常对照组和模型对照组,每孔容量为3mL。于28℃条件下避光孵育5h后,每个实验组随机选取10尾斑马鱼置于荧光显微镜下拍照,用高级图像处理软件分析并采集数据,分析斑马鱼尾鳍区域中性粒细胞数量(N),根据公式计算样品的修护功效,判断其是否具有修护功效,结果见表4。该样品功效实验表型图,如图3所示。
表4九节茶提取物C修护功效评价试验
在本次实验条件下,九节茶提取物C的斑马鱼尾鳍区域中性粒细胞数量与模型对照组相比,明显减少,揭示了该样品具有修护功效。
实施例5:包含本发明九节茶提取物的舒缓修护精华液的功效测试
将实施例1中步骤2所示九节茶提取物C,按表5中的配比制备舒缓修护精华液,用于测试。
表5包含本发明九节茶提取物的舒缓修护精华液配方
| 组分 | 含量% |
| 九节茶提取物C | 3.00 |
| 甘油 | 6.00 |
| 透明质酸钠 | 0.10 |
| 卡波姆 | 0.20 |
| 氢氧化钠 | 0.04 |
| EDTA二钠 | 0.05 |
| 甜菜碱 | 1.00 |
| 烟酰胺 | 0.50 |
| 泛醇 | 0.50 |
| 甘草酸二钾 | 0.05 |
| 丙二醇 | 4.00 |
| 对羟基苯乙酮 | 0.30 |
| 1,2-戊二醇 | 0.35 |
| 1,2-己二醇 | 0.40 |
| 水 | 余量 |
1.皮肤安全性评估
每组按受试者入选标准选择30名参加试验的人员,15名男性,15名女性,平均年龄为32岁。将受试物放入斑试器内,用量约0.020mL-0.025mL液体(液体)。对照孔为空白对照(不置任何物质),将加有受试物的斑试器用低致敏胶带贴敷于受试者的背部或前臂曲侧,用手掌轻压使之均匀地贴敷于皮肤上,持续24h。去除受试物斑试器后(待压痕消失)0.5、24、48小时观察皮肤反应,按《化妆品安全技术规范》(2015年版)中皮肤反应分级标准记录其结果,具体见表6。
表6皮肤安全性测试结果
如表6中的结果可知,测试产品对皮肤没有产生刺激,因此可得出包含本发明九节茶提取物的化妆品组合物对皮肤是安全的。
2.舒缓修护功效测试
选取30名18-40岁符合试验要求的健康男女性,平均年龄19.23岁,面部皮肤有敏感,乳酸刺激测试评分大于5分,泛红及紧绷、刺痛等问题,通过人体测试28天进行舒缓修护临床功效评价。具体测试方法为每天2次,早晚各1次,洁面正常使用爽肤水后,取适量测试物均匀涂抹于脸部肌肤,连续使用28天,并分别于使用前和第7和28天测定皮肤角质层含水量、皮肤经表皮失水率及面部图像采集,测试结果如下:
2.1皮肤角质层含水量测量
本次试验30名受试者使用测试产品后,皮肤角质层含水量的检测结果见表7。
表7面部皮肤角质层含水量的差异性分析
试验结果显示,与基线值(D0)相比,皮肤角质层含水量在D7及D28回访时分别上升了12.9%和26.7%。经重复测量方差分析,整体结果呈显著差异(p=2.67*10-23<0.05)。以D0为基准线,组内差异显示D7和D28回访时的皮肤角质层水分含量表现出显著性差异(p<0.05),可见使用测试样品后,受试者皮肤水分显著增加,即测试物具有一定的补水保湿效果。
2.2皮肤经表皮失水率(TEWL)
本次试验中共20名受试者通过乳酸测试,表明该20名受试者皮肤易受损较敏感。使用测试产品后,皮肤经表皮失水率检测结果见表8。
表8面部皮肤经表皮失水率的差异性分析
试验结果显示,与基线值(D0)相比,皮肤经表皮失水率在D7和D28回访时分别减少了19.3%和30.1%。经重复测量方差分析,整体结果呈显著差异(p=7.44*10-7<0.05)。以D0为基准线,组内差异显示D7和D28回访时的皮肤经表皮失水率表现出显著性差异(p<0.05),可见受试者使用测试样品后,面部皮肤TEWL值均普遍降低,即经皮流失的水分减少,表明该测试物对受损皮肤有修复功效。
本次试验另10名受试者进行斑贴测试(手臂前屈),建立皮肤受损状态,该10名受试者斑贴部位(手臂前屈)使用测试产品后,皮肤经表皮失水率检测结果见表9。
表9皮肤经表皮失水率(斑贴手臂前屈)的差异性分析
试验结果显示,与基线值(D0)相比,皮肤经表皮失水率在D7和D28回访时分别减少了29.4%和42.7%。经重复测量方差分析,整体结果呈显著差异(p=5.0*10-6<0.05),以D0为基准线,组内差异显示D7和D28回访时的皮肤经表皮失水率表现出显著性差异(p<0.05),可见受试者使用测试样品后,皮肤TEWL值均普遍降低,即经皮流失的水分减少,表明该测试物对受损皮肤有修复功效。
2.3面部图象采集
皮肤屏障受损,肌肤容易出现泛红、紧绷及刺痛等炎症状况。通过采集受试者使用测试产品D7和D28 VISIA 7拍摄的面部红区图以及D0和D28自然光下拍摄的图片进行效果比对。如图4和图5所示,受试者使用测试产品后,红区面积明显减少或变淡,皮肤问题得到改善。
显然,本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样,倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内,则本发明也意图包含这些改动和变型在内。
Claims (7)
1.一种具有舒缓修护功能的九节茶提取物的制备方法,其特征在于:所述九节茶提取物是颜色为淡黄色的提取物C,所述提取物C中迷迭香酸与异嗪皮啶的重量比为10-13:1,所述九节茶提取物的制备方法如以下步骤所示:
步骤1:提取和浓缩:取九节茶净药材,粗碎后投入提取罐内煎煮,加5-20倍量水煎煮1-10小时,从沸腾后开始计时,煎液过滤,合并滤液,将滤液在减压装置下≤ 80℃浓缩即得九节茶粗浸膏,即提取物A;
步骤2:提纯和脱色:将步骤1中制备得到的所述提取物A加入适量硅胶,拌样后经硅胶柱层析用4-6倍柱体积的层析液体积分数40%-95%乙醇-水溶液洗脱,收集洗脱液浓缩,得浓缩液,即提取物B;将所述提取物B加入适量硅胶,拌样后经硅胶柱层析第一次用2-3倍柱体积的石油醚洗脱,弃去洗脱液,第二次用4-6倍柱体积的乙酸乙酯:乙醇:水=75%-89%:20%-10%:1%混合溶液洗脱,收集洗脱液浓缩,得浓缩液,即提取物C;在步骤2中的所述浓缩均在减压装置下≤ 80℃进行;
所述九节茶净药材为金粟兰科植物九节茶Sarcandra glabra (Thunb.)Nakai的干燥全草。
2.采用权利要求1所述的制备方法制备得到的九节茶提取物在制备具有舒缓修护功能的皮肤外用产品中的用途。
3.根据权利要求2所述的用途,其特征在于:所述皮肤外用产品为药物。
4.根据权利要求2所述的用途,其特征在于:所述皮肤外用产品为化妆品。
5.根据权利要求2所述的用途,其特征在于:所述皮肤外用产品为洗护用品。
6.采用权利要求1所述的制备方法制备得到的九节茶提取物在制备具有舒缓修护功能的口腔清洁类产品中的用途。
7.根据权利要求2或权利要求6所述的用途,其特征在于:以重量百分比计,所述九节茶提取物的用量为0.01%-3.12%。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310434537.8A CN116211902B (zh) | 2023-04-21 | 2023-04-21 | 一种具有舒缓修护功能的九节茶提取物及其制备方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310434537.8A CN116211902B (zh) | 2023-04-21 | 2023-04-21 | 一种具有舒缓修护功能的九节茶提取物及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116211902A CN116211902A (zh) | 2023-06-06 |
| CN116211902B true CN116211902B (zh) | 2024-07-16 |
Family
ID=86575309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310434537.8A Active CN116211902B (zh) | 2023-04-21 | 2023-04-21 | 一种具有舒缓修护功能的九节茶提取物及其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116211902B (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108670973A (zh) * | 2018-05-07 | 2018-10-19 | 福建中医药大学 | 一种草珊瑚抗流感病毒活性提取物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101664512B (zh) * | 2009-09-15 | 2011-05-11 | 江西天施康中药股份有限公司 | 一种含肿节风提取物中药制剂的制备方法 |
| CN104042520A (zh) * | 2014-06-30 | 2014-09-17 | 广西润深农林科技有限公司 | 草珊瑚流浸膏水提醇沉工艺方法 |
| CN113274319A (zh) * | 2021-03-23 | 2021-08-20 | 麦和(广州)实业有限公司 | 一种晒后舒缓修护及提亮的护肤组合物及制备方法、应用 |
-
2023
- 2023-04-21 CN CN202310434537.8A patent/CN116211902B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108670973A (zh) * | 2018-05-07 | 2018-10-19 | 福建中医药大学 | 一种草珊瑚抗流感病毒活性提取物及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 草珊瑚流浸膏的性能及在化妆品中的应用;胡国顺;日用化学工业(04);第61页1性能,第62页1.3异嗪皮啶,第63页2应用 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116211902A (zh) | 2023-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE10262193B4 (de) | Kosmetische Verwendung eines Wirkstoffs zur Stimulierung der humanen beta-Defensine vom Typ 2 und/oder Typ 3, Verwendung eines solchen Wirkstoffs zur Herstellung einer pharmazeutischen Zusammensetzung, die einen solchen Wirkstoff enthält und Verwendung eines solchen Wirkstoffs auf dem Gebiet der Geweberekonstruktion | |
| TW457094B (en) | Topical composition for enhancing lipid barrier synthesis | |
| BRPI0808065A2 (pt) | Novas composições cosméticas e/ou farmacêuticas e suas aplicações | |
| TW200826971A (en) | Compositions and methods of their use for improving the condition and appearance of skin | |
| KR20040068986A (ko) | 줄기 세포 인자의 생산ㆍ방출의 억제에 의한 소양, 피부거칠어짐, 민감성 피부 개선용 및 미백용 약제 | |
| US20250345265A1 (en) | Active principle comprising a particular extract of punica granatum and uses for preventing and/or treating acne | |
| KR102429343B1 (ko) | 복합 생약 추출물 유효성분으로 포함하는 두피 및 모발개선용 화장료 조성물. | |
| KR102083294B1 (ko) | 피부재생 효과를 갖는 미선나무 추출물 및 그 추출물을 함유하는 피부재생용 조성물 | |
| JPH07126146A (ja) | 皮膚外用剤 | |
| US20190151395A1 (en) | Daphne laureola extracts in the treatment of dermopathies | |
| KR101547758B1 (ko) | 탈모 예방 및 양모, 육모 촉진용 조성물 | |
| TWI476012B (zh) | 使用茄屬植物的水溶性萃取物來治療和/或預防發炎與皮膚光損害以及光防護皮膚 | |
| CN116211902B (zh) | 一种具有舒缓修护功能的九节茶提取物及其制备方法和用途 | |
| WO2005002608A1 (en) | Herbal composition | |
| KR102353372B1 (ko) | 수벌번데기 추출물을 포함하는 탈모방지 또는 육모촉진용 조성물 | |
| KR20130038925A (ko) | 헤스페레틴의 신규 용도 | |
| JPH10175859A (ja) | 津液改善用皮膚外用剤 | |
| JP4018764B2 (ja) | 津液改善用皮膚外用剤 | |
| JP3235919B2 (ja) | 化粧料 | |
| CN117412755A (zh) | 包含植物来源的外泌体样纳米囊泡或外泌体的组合物及其使用方法 | |
| KR20220078293A (ko) | 크리소에리올을 포함하는 멜라닌 생성 촉진용 조성물 | |
| JP2002521453A (ja) | メラニン色素の合成を刺激する組成物およびその製造方法 | |
| JP2011219403A5 (zh) | ||
| JP3113009B2 (ja) | 美白化粧料 | |
| JPH10120561A (ja) | 津液改善用皮膚外用剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |